We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+45.97%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
+$1.91B
Cap. Flow
+$58.2M
Cap. Flow %
0.82%
Top 10 Hldgs %
40.22%
Holding
232
New
17
Increased
84
Reduced
52
Closed
24

Top Buys

Rank Stock Value
1
GBIO
Generation Bio
GBIO
+$32.1M
2
SYK icon
Stryker
SYK
+$27.9M
3
PODD icon
Insulet
PODD
+$24.7M
4
BMY icon
Bristol-Myers Squibb
BMY
+$24.3M
5
DVA icon
DaVita
DVA
+$23.4M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$34.5M
3
ILMN icon
Illumina
ILMN
+$34.1M
4
MRNA icon
Moderna
MRNA
+$33.1M
5
AKCA
Akcea Therapeutics Inc
AKCA
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
2 Industrials 0.58%
3 Technology 0.42%
4 Communication Services 0.29%
5 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
101
BeOne Medicines Ltd
ONC
$32.2B
$10.9M 0.15%
58,000
-500
-0.9% -$81.4K
IRTC icon
102
iRhythm Holdings
IRTC
$3.66B
$10.8M 0.15%
93,140
-40,119
-30% -$4.42M
PHR icon
103
Phreesia
PHR
$660M
$10.7M 0.15%
377,169
+16,171
+4% +$421K
CDTX
104
DELISTED
Cidara Therapeutics
CDTX
$10.4M 0.15%
141,125
– –
GILD icon
105
Gilead Sciences
GILD
$165B
$10.3M 0.15%
134,500
-10,000
-7% -$766K
SILK
106
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$10.3M 0.15%
245,338
+50,755
+26% +$1.95M
GH icon
107
Guardant Health
GH
$19.6B
$10.3M 0.15%
126,561
+21,267
+20% +$1.71M
HCAT icon
108
Health Catalyst
HCAT
$160M
$10.2M 0.14%
349,169
+96,169
+38% +$2.66M
BMRN icon
109
BioMarin Pharmaceuticals
BMRN
$11.4B
$9.48M 0.13%
76,900
+4,800
+7% +$477K
IART icon
110
Integra LifeSciences
IART
$1.47B
$9.44M 0.13%
200,897
+3,477
+2% +$171K
SGEN
111
DELISTED
Seagen Inc. Common Stock
SGEN
$9.33M 0.13%
54,900
+13,500
+33% +$2.01M
LH icon
112
Labcorp
LH
$23.1B
$9.01M 0.13%
63,128
+42,338
+204% +$5.86M
OXFD
113
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$8.89M 0.13%
683,795
+21,480
+3% +$258K
HZNP
114
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.79M 0.12%
158,200
-7,800
-5% -$334K
XENT
115
DELISTED
Intersect ENT, Inc
XENT
$7.62M 0.11%
563,090
+18,068
+3% +$210K
TMDX icon
116
Transmedics
TMDX
$2.54B
$7.62M 0.11%
+425,000
New +$6.65M
VCRA
117
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$7.29M 0.1%
344,081
-6,643
-2% -$130K
COO icon
118
Cooper Companies
COO
$14B
$7.19M 0.1%
101,380
– –
XRAY icon
119
Dentsply Sirona
XRAY
$2.7B
$7.01M 0.1%
159,129
+31,091
+24% +$1.31M
DGX icon
120
Quest Diagnostics
DGX
$23B
$6.84M 0.1%
+60,005
New +$6.36M
AVTR icon
121
Avantor
AVTR
$7.28B
$6.2M 0.09%
364,877
+50,311
+16% +$819K
LEGN icon
122
Legend Biotech
LEGN
$4.49B
$5.71M 0.08%
+134,261
New +$5.25M
INGN icon
123
Inogen
INGN
$173M
$5.29M 0.07%
148,912
+25,517
+21% +$1.08M
QTNT
124
DELISTED
Quotient Limited Ordinary Shares
QTNT
$4.43M 0.06%
14,979
+6,082
+68% +$1.75M
NUVA
125
DELISTED
NuVasive, Inc.
NUVA
$3.7M 0.05%
+66,500
New +$3.85M
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2020 Portfolio in Review

As of Q2 2020, Bellevue Group held 232 positions worth $7.07B, up 37% from $5.16B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group's Q2 2020 filing shows 17 new, 84 increased, 52 reduced and 24 closed positions. Its largest new stake was Generation Bio: 144,000 shares worth $30.2M. The largest sale was Vertex Pharmaceuticals, an estimated $78.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2020 buy was Generation Bio: 144,000 shares worth $30.2M.
  • Bellevue Group added most to Stryker in Q2 2020, an estimated $27.9M increase.
  • Bellevue Group's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $78.8M.
  • Bellevue Group fully exited QuidelOrtho in Q2 2020, selling an estimated $11.1M.
  • Bellevue Group's ten largest holdings make up 40% of its $7.07B portfolio in Q2 2020.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2020.
  • Bellevue Group's portfolio value rose 37% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.